Breaking: Miragen Therapeutics Inc (MGEN) “Buy” Rating Reiterated by Wedbush Today; The Price Objective is Set to $19.0000

June 8, 2018 - By Winifred Garcia

Miragen Therapeutics Inc (MGEN) Rating Reaffirmed

EU: In a research note released on Thursday morning, Wedbush kept their “Buy” rating on Miragen Therapeutics Inc (MGEN) shares. They now have a $19.0000 target price per share on the company. Wedbush’s target suggests a potential upside of 155.38 % from the company’s stock close price.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 7 analysts covering miRagen Therapeutics Inc (MGEN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. miRagen Therapeutics Inc has $19 highest and $1300 lowest target. $16.29’s average target is 118.95% above currents $7.44 stock price. miRagen Therapeutics Inc had 19 analyst reports since January 4, 2018 according to SRatingsIntel. The company was initiated on Wednesday, March 28 by Wedbush. The firm has “Buy” rating by FBR Capital given on Thursday, March 15. The stock has “Buy” rating by FBR Capital on Friday, February 2. On Thursday, May 10 the stock rating was maintained by FBR Capital with “Buy”. As per Monday, June 4, the company rating was maintained by FBR Capital. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) earned “Buy” rating by Oppenheimer on Thursday, January 11. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) earned “Buy” rating by Oppenheimer on Tuesday, March 27. Wedbush maintained Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Tuesday, March 20 with “Buy” rating. The firm has “Buy” rating by FBR Capital given on Tuesday, March 27. On Thursday, May 17 the stock rating was maintained by FBR Capital with “Buy”.

The stock decreased 0.67% or $0.05 during the last trading session, reaching $7.44. About 145,017 shares traded. Miragen Therapeutics, Inc. (MGEN) has declined 34.18% since June 8, 2017 and is downtrending. It has underperformed by 46.75% the S&P500.

Analysts await Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report earnings on August, 10. They expect $-0.29 EPS, up 14.71 % or $0.05 from last year’s $-0.34 per share. After $-0.18 actual EPS reported by Miragen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 61.11 % negative EPS growth.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $224.63 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More important recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: Benzinga.com which released: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” on June 03, 2018, also Seekingalpha.com published article titled: “miRagen Therapeutics’ (MGEN) CEO William Marshall on Q1 2018 Results – Earnings Call Transcript”, Nasdaq.com published: “miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” on May 09, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) was released by: Nasdaq.com and their article: “miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th” with publication date: May 18, 2018.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.